The Empagliflozin in Acute Myocardial Infarction (EMMY) trial investigated the effect of empagliflozin compared with placebo on NT‐proBNP concentrations in 476 patients within 72 h of a large acute MI (defined by creatine kinase >800 IU/L or troponin assay >10× upper limit of normal).42 This evidence concerns the gene NPPB and myocardial infarction.